Skip to main content

Table 1 Demographic and clinical characteristics of SLE patients

From: Dysfunctional interferon-α production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus

Characteristic

SLE patients (n = 43)

Age (years; mean [range])

35.0 (21 to 56)

Sex (n; males/females)

2/41

Disease duration (years; mean [range])

8.5 (0.1 to 18)

SLEDAI (mean ± SD)

3.72 ± 3.84

   Active (n = 9)a

9.55 ± 4.50

   Inactive (n = 34)

2.17 ± 1.42

Cutaneous manifestation (n [%])

26 (60.5)

Arthritis (n [%])

27 (62.8)

Renal manifestation (n [%])

9 (20.9)

Cytopenia (n [%])

11 (25.6)

Serositis (n [%])

8 (18.6)

Prednisolone (n [%]; mean dosage [mg/day])

41 (95.3); 13.0

Hydroxychloroquine (n [%])

34 (79.1)

Azathioprine (n [%])

4 (9.3)

Cyclosporin (n [%])

1 (2.3)

Mizoribine (n [%])

4 (9.3)

Mycophenolate mofetil (n [%])

3 (7.0)

  1. aSystemic Lupus Erythematosus Disease Activity Index above 4. SD, standard deviation; SLE, systemic lupus erythematosus.